Eprinex

Eprinomectin

Method of action: Endectocides

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eprinex

What is Eprinex? Overview

Property	Description
Active Ingredient	Eprinomectin
Form	Pour-on Solution (Topical)
Pharmacological Class	Macrocyclic Lactone (Avermectin Subclass)
Common Use	Treatment and control of parasitic infections in livestock
Origin	Semi-synthetic (derived from microbial fermentation)

Defining Eprinex: What Type of Veterinary Medicine is It?

Eprinex is a specialized, broad-spectrum veterinary medicine product administered as a non-aqueous pour-on solution intended for topical application along the animal’s backline. The medicine is classified as an endectocide, meaning it is clinically recognized for its ability to target both internal and external parasitic infections and infestations in livestock. Its use in dairy cattle is notable, as its specific regulatory status allows for use without requiring a milk discard time. This distinctive regulatory allowance simplifies the management of treated animals. The chosen delivery system, the pour-on solution, is a differentiating feature that simplifies the external use only administration in large herds, contrasting with traditional injectable forms.

Eprinomectin: Composition, Origin, and Pharmacological Class

The medicine’s therapeutic effect stems entirely from its sole active ingredient, Eprinomectin, which belongs to the potent Macrocyclic Lactone family, specifically the Avermectin subclass. Eprinomectin is defined chemically as a semi-synthetic derivative, structurally modified from compounds initially produced during the fermentation process involving the microorganism Streptomyces avermitilis. Pharmacological studies support its effectiveness against a wide range of common parasitic infections. The formulation is presented as a clear, colorless to slightly yellow liquid containing the Eprinomectin at a standard 5 mg/mL concentration in its non-aqueous liquid vehicle.

General Purpose: What Does Eprinomectin Help to Control?

The general purpose of the Eprinomectin compound is to achieve effective paralysis and subsequent death of the parasite by selectively disrupting its neuromuscular function. This fundamental physiological action allows the product to offer robust treatment and control of parasitic infections in the animal host. This mode of action is achieved because the drug is a member of the macrocyclic lactone class, compounds known to bind specifically to target receptors in invertebrate nerve and muscle cells. The result is a substantial benefit in managing the broad-spectrum of organisms that cause common parasitic infections and infestations in livestock.

Regulatory References

FDA FOI Summary (NADA 141-079)

What side effects are possible with Eprinex?

Possible Side Effects and Safety Information

The regulatory safety profile for Eprinomectin (Eprinex pour-on) primarily addresses potential local reactions and specific safety constraints documented in official government sources.

Frequency and Organ Class Affection

Adverse reactions associated with the use of Eprinomectin pour-on are officially classified as Very Rare, meaning they are observed in less than 1 in 10,000 treated animals. These effects are generally transient and predominantly fall under the following system-organ classes:

Skin and Subcutaneous Tissue Disorders: Includes minor local reactions, such as temporary pruritus (itching), alopecia (hair loss), skin scales, and transient licking reactions at the application site.
Nervous System Disorders: Localized skin tremor at the site of application has been documented.

Serious Safety Considerations

The regulatory label highlights high-level safety constraints beyond routine adverse reactions:

Secondary Reactions to Larvae Death: A risk of severe clinical signs, including staggering or paralysis, exists if the product is administered during a specific migratory phase of certain parasites, such as Hypoderma larvae, in sensitive areas of the body.
Toxicity in Non-Target Species: The avermectin class of compounds is known to be toxic to certain non-target animals, including specific dog breeds and chelonians (turtles/tortoises), with mortality reported upon exposure.

Population-Specific Safety and Constraints

Safety has been established and documented for use in pregnant cattle, lactating cattle, and reproductive bulls. Critical safety constraints include the product's classification as very toxic to dung fauna and aquatic organisms due to environmental persistence. Furthermore, a regulatory withdrawal period must be observed before treated cattle can be slaughtered for human consumption.

Overdose and Emergency Response

Overdose and When to Seek Help

This section addresses officially documented overdose information for Eprinex (Eprinomectin), primarily focused on safety data from regulatory sources regarding accidental human exposure and toxicity in non-target species.

Documented Overdose Profile

In target animals (cattle), regulatory studies indicate a high safety margin, with no systemic signs of toxicity observed when the drug was administered at up to five times the recommended dose.

For human accidental exposure, the official safety profile advises that ingestion may affect the central nervous system. Serious adverse events, including fatalities, have been documented if the product is administered to non-target animal species, such as dogs.

Overdose Component	Official Regulatory Statement
Antidote Information	No specific antidote has been identified for eprinomectin toxicity.
Management Approach	Treatment is strictly symptomatic and supportive.

Required Emergency Actions

Urgent medical attention is necessary following accidental human ingestion or if a person feels unwell after exposure. In such cases, the person must seek medical advice immediately and show the product label or package insert to the physician. For accidental skin contact, the affected area must be washed immediately with soap and water; for eye contact, flush the eyes immediately with water.

Therapeutic Uses of Eprinex

What Eprinex Treats: Main Uses and Benefits

Eprinex is relevant across domains where additional symptomatic support is needed, specifically targeting discomfort caused by a wide range of parasitic infestations in cattle. It is commonly used to help with conditions presenting with systemic or localized discomfort due to these parasites. This approach assists with supporting functional stability and contributes to easing the overall symptom load during periods of heightened distress.

Key Therapeutic Domains

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, often used during phases when symptoms become more noticeable. Its indications include managing issues caused by major internal parasites like gastrointestinal and lungworms, as well as common external parasites such as lice and mange mites.

Eprinex is relevant for managing symptoms that interfere with daily comfort. It assists with symptomatic management during periods of strain, which helps maintain a sense of stability when discomfort becomes more noticeable.

“It is commonly used across conditions characterized by periods of heightened symptoms, offering symptomatic relief that helps manage physiological strain.”

Quick Fact: Supports Management of Irritative Symptoms This medication is often used in contexts involving symptoms related to inflammatory or irritative states caused by internal or external parasitic activity.

Regulatory References

NIH DailyMed Label for Eprinomectin

Eligibility and Restrictions for Use

The eligibility for using Eprinex (Eprinomectin) pour-on solution is strictly governed by regulatory classifications, limiting its use to approved species and ruling out specific conditions.

Approved Populations and Contraindications

Eligibility Status	Official Regulatory Rule
Approved Population	Beef and dairy cattle of all ages, including cows and bulls.
Absolute Contraindication	Use is prohibited in non-target animal species. This includes dogs and turtles/tortoises, as avermectins may be fatal to these animals.
Specific Prohibited Use	Not for use in calves to be processed for veal (US restriction).
Hypersensitivity	Contraindicated in animals with a known allergy or hypersensitivity to Eprinomectin or any of the product's excipients.

Use Under Physiological States and Restrictions

Regulatory documentation defines Eprinex eligibility during key physiological states and specifies restrictions on the method of application:

Pregnancy and Lactation: The product is explicitly permitted for use in pregnant cows and lactating dairy cattle. It is approved with a zero milk discard time.
Route of Administration: The solution is formulated for topical application only; it must not be administered orally or by injection.
Conditional Use: Treatment must be timed appropriately to avoid potential adverse reactions, such as those related to the destruction of Hypoderma larvae during the warble fly season.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Eprinex (eprinomectin pour-on solution) is characterized by the absence of known specific drug-drug interactions in the target species. Regulatory documentation from national and international agencies consistently states that no interactions with other medicinal products are known.

This means that the official product label does not list any specific compounds, product classes, or dietary components (such as food or herbal supplements) that are formally contraindicated or require mandatory timing separation rules for co-administration. Consequently, no specific contraindicated combinations or timing-based interaction rules are documented in the official prescribing information.

Pharmacokinetic Caution

The interaction profile does include a formal regulatory caution concerning the drug's fundamental pharmacokinetic properties. The active ingredient, eprinomectin, is documented as binding strongly and extensively to plasma proteins. This strong plasma protein binding characteristic should be taken into account if the medicine is used concurrently with other molecules having the same strong plasma protein binding properties.

This caution represents the singular documented focus for potential exposure-modifying interactions described by the regulatory authority, where competition for binding sites could theoretically alter the concentration of the co-administered compound.

Mechanism of Action

Eprinex (eprinomectin) targets critical neurological pathways exclusively in parasites. Its pharmacodynamic mechanism focuses on modulating ion channels within the invertebrate nervous system through a high degree of selectivity over mammalian homologs.

Eprinomectin acts as a positive allosteric modulator and agonist, binding to glutamate-gated chloride ion channels found in invertebrate nerve and muscle cells. This interaction is the core mechanistic event, causing a significant increase in the cell membrane's permeability to chloride ions (Cl^-).

This resultant influx of negative charge induces hyperpolarization of the neuronal and muscle membranes, making them less responsive to excitatory stimuli. This pathway effect leads to the physiological consequence of sustained parasite paralysis and subsequent disruption of vital functions. The compound's selectivity profile is maintained because mammals lack the primary target channel and exhibit low affinity for related mammalian ligand-gated chloride channels.

Dosage and Administration Information

How to Use Eprinex: Official Administration Guidelines

Eprinex is administered strictly according to high-level procedural principles for the use of its 5 mg/ mL pour-on solution. The administration process is standardized, focusing on precision in dosing and correct application technique.

Official Administration Protocol

Field	Instruction
Route of administration	Topical application (pour-on solution) only; strictly for external use
Dosing schedule (official)	1 mL of solution applied for every 10 kg of the animal's body weight, delivering a mass dose of 500 mcg Eprinomectin per kg
Frequency pattern	Single application per treatment event, as guided by the parasite control program
Target populations	Approved for use in beef and dairy cattle of all ages, including lactating animals

Procedural and Dosing Requirements

Administration is characterized by precise logistical and dosing constraints. The entire measured dose must be applied along the animal's backline in a narrow strip, extending from the area of the withers to the tailhead. Accurate body weight determination is mandatory for calculating the correct volume to prevent underdosing, and the solution must not be applied to areas of the backline that are visibly soiled by mud or manure. The product is used as supplied without any requirement for dilution or reconstitution.

These instructions define the mandatory operational steps for delivering the specified dose of Eprinomectin via the approved topical route, ensuring procedural adherence to the conditions outlined in the product's official documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eprinex

The research evidence for Eprinex (eprinomectin pour-on) includes controlled clinical studies and field trials that were conducted for regulatory review. These studies explore the medicine in research settings focused on target parasites and other measures, such as production outcomes.

Evidence for Gastrointestinal and Lungworm Infections

Research exploring Eprinex in studies focused on major internal parasites, such as gastrointestinal and lungworms, has relied on controlled efficacy studies and randomized trials. These studies focused on specific measures to quantify the presence of parasitic organisms in cattle. Researchers commonly monitored outcomes related to Parasite Count Reduction and Fecal Egg Count Reduction (FECR).

The core regulatory evidence included measurements that described differences in the count of adult and larval internal worms between treated and control populations at the time of assessment. Some studies also explored persistent efficacy, which describes the duration during which the medicine's presence was associated with protection from new parasitic establishment. The study populations included both dairy and beef cattle, including lactating cows and young animals.

Research on Indirect Effects and Production Parameters

Beyond research on parasite counts, studies have explored other factors, such as production parameters, in treated populations. These studies were structured as randomized controlled field trials with observation periods extending over several months. The outcomes monitored were indirect measures of health and performance, specifically changes in Body Weight Gain over the study duration compared to untreated control groups.

Trials described patterns where the treated groups achieved higher weight measurements compared to the untreated control groups, particularly in growing cattle. Findings indicated that the magnitude of these differences was often related to the initial level of parasitic infection present in the herd.

What Remains Uncertain and Research Gaps

Despite the available evidence, certain limitations and research gaps have been noted. The follow-up durations were often limited, meaning there is limited information for long-term outcomes beyond a few months. Data for monitoring resistance development over extended periods remain insufficient in publicly available regulatory summaries. Additionally, outcomes like weight gain are subject to significant variability across studies due to external factors like feed quality and genetics.

Key Studies & References EPRINEX POUR-ON FOR BEEF AND DAIRY CATTLE- eprinomectin solution - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Eprinex (FAQ)

Q: What is Eprinex (eprinomectin)?

A: Eprinex is the brand name for a veterinary medicine containing the active ingredient eprinomectin. It belongs to a class of antiparasitic drugs called macrocyclic lactones (specifically, an avermectin derivative). It is designed as a pour-on solution for the treatment and control of various internal and external parasites in cattle, including gastrointestinal roundworms, lungworms, and biting/sucking lice. Its primary use is in livestock.

Q: Is Eprinex safe for human use or consumption?

A: No, Eprinex is not safe for human use or consumption. It is an animal drug approved exclusively for veterinary use in livestock, particularly cattle. The formulation and dosage are intended for animals. Humans should never ingest or use veterinary medications, as this can lead to serious health risks, including potential toxicity or adverse effects.

Q: How does Eprinex work to eliminate parasites?

A: Eprinex (eprinomectin) works by targeting the nervous system of the parasites. It binds to glutamate-gated chloride ion channels found in the nerve and muscle cells of the parasites. This binding increases the permeability of the cell membrane to chloride ions. The resulting influx of chloride ions leads to hyperpolarization of the nerve cell, causing the parasite's paralysis and eventual death. Because these channels are not present in mammals, it gives the drug a specific action against the target parasites.

Q: How is Eprinex administered to cattle?

A: Eprinex is formulated as a pour-on solution. This means it is applied externally along the backline of the animal, typically from the withers to the base of the tail. The active ingredient is then absorbed through the skin and distributed throughout the animal's system to effectively reach and eliminate both internal and external parasites.

Q: What is the milk and meat withdrawal time for Eprinex in cattle?

A: A significant feature of Eprinex is that it has a zero milk withdrawal period when used according to label instructions. This allows it to be used in lactating dairy cattle without requiring milk to be discarded. However, it does have a meat withdrawal time which must be observed to ensure the safety of the food supply. Users must strictly follow the official product label and local regulatory guidelines for the specific withdrawal periods to ensure compliance and public safety.

How should Eprinex be stored and disposed of?

The official regulatory requirements for Eprinex (eprinomectin Pour-On) define strict conditions for storage and disposal to ensure product stability and environmental safety.

Storage/Disposal Requirement	Official Regulatory Statement
Storage Temperature	Store at temperatures up to 86 F (30 C). Short-term exposure up to 104 F (40 C) must be minimized.
Light Protection	Store in the original container and outer carton to protect from light.
Child Safety	Must be kept out of the sight and reach of children.
Disposal	Dispose of unused product and waste in accordance with local requirements (e.g., approved landfill or incineration).
Environmental Rule	Do not contaminate watercourses. The product is dangerous for fish and aquatic organisms.